医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Mazor Robotics’ Renaissance System Highlighted in Special Session at the Joint Congress of the Chinese Association of Orthopaedic Surgeons and North American Spine Society

2015年05月28日 PM05:30
このエントリーをはてなブックマークに追加


 

CAESAREA, Israel

Mazor Robotics (TASE:MZOR; NASDAQ GM:MZOR), a developer of innovative guidance systems and complementary products, announced that Dr. Isador Lieberman, a leading orthopaedic spine surgeon from Dallas, Texas, performed a live surgical procedure using the Company’s Renaissance® system at the Joint Congress of the Chinese Association of Orthopaedic Surgeons and North American Spine Society. The procedure was performed in front of 1,000 attending surgeons.

During his two week trip to China, Dr. Lieberman visited several hospitals across the country and presented the clinical benefits of robotic spine surgery. Since 2010, Dr. Lieberman has been the head of the Scoliosis and Spine Tumor Unit at Texas Back Institute in Plano, Texas. He was previously head of the Cleveland Clinic’s Spine Program in Florida.

“The spine market is one of the fastest growing segments in the Chinese surgery market. The size of the market and the continued adoption of new technologies make it an ideal opportunity for Mazor Robotics,” said Ori Hadomi, Mazor’s Chief Executive Officer. “Our presence at the conference and the live demonstration by Dr. Lieberman, which was observed by 1,000 surgeons, allowed us to increase the awareness of Renaissance while reinforcing the applicability and relevance to the Chinese market.”

Last September, the China Food and Drug Administration (CFDA) approved the Company’s Renaissance system for use in the country, allowing Mazor to begin marketing the system in China. Additionally, Mazor signed a distribution partnership with Beijing-based Cicel Science & Technology Co., LTD (“Cicel”), a leading medical equipment distributor with a deep knowledge of the market. Cicel has purchased two Renaissance systems since the CFDA approval.

Renaissance improves the execution and results in a wide variety of spine procedures, including minimally-invasive approaches, for both degenerative spine disease and spinal deformity. To date, Renaissance has been used in over 1,000 spinal deformity corrections and thousands of minimally invasive procedures.

For a full list of 2015 events and conferences attended by Mazor, visit http://mazorrobotics.com/surgeons/events/.

About Mazor

Mazor Robotics (TASE:MZOR; NASDAQGM:MZOR) believes in healing through innovation by developing and introducing revolutionary robotic-based technology and products aimed at redefining the gold standard of quality care. Mazor Robotics Renaissance® Guidance System enables surgeons to conduct spine and brain procedures in a more accurate and secure manner. For more information, please visit www.MazorRobotics.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Any statements in this release about future expectations, plans or prospects for the Company, including without limitation, statements regarding the growth of and size of the spine market in China, that the Chinese market is a promising opportunity for Mazor, and other statements containing the words “believes,” “anticipates,” “plans,” “expects,” “will” and similar expressions are forward-looking statements. These statements are only predictions based on Mazor’s current expectations and projections about future events. There are important factors that could cause Mazor’s actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements. Those factors include, but are not limited to, the impact of general economic conditions, competitive products, product demand and market acceptance risks, reliance on key strategic alliances, fluctuations in operating results, and other factors indicated in Mazor’s filings with the Securities and Exchange Commission (SEC) including those discussed under the heading “Risk Factors” in Mazor’s annual report on Form 20-F filed with the SEC on April 29, 2015 and in subsequent filings with the SEC. For more details, refer to Mazor’s SEC filings. Mazor undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or to changes in our expectations, except as may be required by law.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150528005417/en/

CONTACT

U.S.: EVC Group
Investors
Michael Polyviou/Doug Sherk,
212-850-6020; 415-652-9100
mpolyviou@evcgroup.com;
dsherk@evcgroup.com
or
Media
David
Schemelia, 646-201-5431
dave@evcgroup.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • BioVectra与Keryx Biopharmaceuticals签署枸橼酸铁扩产协议
  • Eternity Healthcare Inc. Enters into Share Exchange Agreement with Guizho Tongren Healthy China Biotechnology Co. Ltd.
  • Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease
  • Chi-Med Initiates Fruquintinib U.S. Clinical Trials
  • Orthocell Granted European Tendon Regeneration Patent